Paper42424601
Schlafen 11 Is Overexpressed in Multiple Myeloma and Undergoes Nucleolar Translocation in Response to Bortezomib.
Arakawa Y and 4 others. Cancer Res Commun, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Schlafen 11 Is Overexpressed in Multiple Myeloma and Undergoes Nucleolar Translocation in Response to Bortezomib. Papers, record 42424601. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42424601
- Cell line
- U2OS443 papers
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Schlafen 11 Is Overexpressed in Multiple Myeloma and Undergoes Nucleolar Translocation in Response to Bortezomib.
- PubMed
Connected records4
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Multiple Myeloma | Major topic |
| Bortezomib | Major topic |
| Nuclear Proteins | Major topic |
| Cell Nucleolus | Major topic |
| Humans | |
| Cell Line, Tumor | |
| Gene Expression Regulation, Neoplastic | |
| Antineoplastic Agents |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| Z01 BC006150 | Intramural NIH HHS | United States | Z01BC006150 | PubMed | NIH RePORTER |
| 25K11676 | Japan Society for the Promotion of Science (JSPS) | PubMed | PubMed | ||
| Z01-BC-006150 | National Cancer Institute (NCI) | Z01BC006150 | PubMed | NIH RePORTER |
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Update of | 42051302 | Schlafen 11 (SLFN11) overexpression and nucleolar localization in response to bortezomib in multiple myeloma. | https://conductscience.org/library/papers/42051302 |
Source PubMed
References57
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32444850 | Visualizing and interpreting cancer genomics data via the Xena platform. | Nat Biotechnol | 2020 | https://conductscience.org/library/papers/32444850 | PubMed |
| 2 | 22927417 | Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. | Proc Natl Acad Sci U S A | 2012 | https://conductscience.org/library/papers/22927417 | PubMed |
| 3 | 25779942 | SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma. | Clin Cancer Res | 2015 | https://conductscience.org/library/papers/25779942 | PubMed |
| 4 | 31128155 | Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies. | Pharmacol Ther | 2019 | https://conductscience.org/library/papers/31128155 | PubMed |
| 5 | 33863777 | SLFN11 Inactivation Induces Proteotoxic Stress and Sensitizes Cancer Cells to Ubiquitin Activating Enzyme Inhibitor TAK-243. | Cancer Res | 2021 | https://conductscience.org/library/papers/33863777 | PubMed |
| 6 | 34808009 | Prognostic impact of Schlafen 11 in bladder cancer patients treated with platinum-based chemotherapy. | Cancer Sci | 2022 | https://conductscience.org/library/papers/34808009 | PubMed |
| 7 | 35143610 | blitzGSEA: efficient computation of gene set enrichment analysis through gamma distribution approximation. | Bioinformatics | 2022 | https://conductscience.org/library/papers/35143610 | PubMed |
| 8 | 34294893 | A wake-up call for cancer DNA damage: the role of Schlafen 11 (SLFN11) across multiple cancers. | Br J Cancer | 2021 | https://conductscience.org/library/papers/34294893 | PubMed |
| 9 | 35768579 | Structural, molecular, and functional insights into Schlafen proteins. | Exp Mol Med | 2022 | https://conductscience.org/library/papers/35768579 | PubMed |
| 10 | 29444873 | Hypoxia-inducible KDM3A addiction in multiple myeloma. | Blood Adv | 2018 | https://conductscience.org/library/papers/29444873 | PubMed |
| 11 | 15491288 | Expression of protein gene product 9.5 (PGP9.5)/ubiquitin-C-terminal hydrolase 1 (UCHL-1) in human myeloma cells. | Br J Haematol | 2004 | https://conductscience.org/library/papers/15491288 | PubMed |
| 12 | 33785877 | Schlafen 11 predicts response to platinum-based chemotherapy in gastric cancers. | Br J Cancer | 2021 | https://conductscience.org/library/papers/33785877 | PubMed |
| 13 | 38753784 | DNA damage induces p53-independent apoptosis through ribosome stalling. | Science | 2024 | https://conductscience.org/library/papers/38753784 | PubMed |
| 14 | 17692103 | Plasma cell growth fraction using Ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I. | Eur J Haematol | 2007 | https://conductscience.org/library/papers/17692103 | PubMed |
| 15 | 39185596 | Immunohistochemical Evaluation of Schlafen 11 (SLFN11) Expression in Cancer in the Search of Biomarker-Informed Treatment Targets: A Study of 127 Entities Represented by 6658 Tumors. | Am J Surg Pathol | 2024 | https://conductscience.org/library/papers/39185596 | PubMed |
| 16 | 18174376 | Cell cycle-dependent chromatin loading of the Fanconi anemia core complex by FANCM/FAAP24. | Blood | 2008 | https://conductscience.org/library/papers/18174376 | PubMed |
| 17 | 31227499 | Targeting Topoisomerase I in the Era of Precision Medicine. | Clin Cancer Res | 2019 | https://conductscience.org/library/papers/31227499 | PubMed |
| 18 | 20574050 | Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. | Blood | 2010 | https://conductscience.org/library/papers/20574050 | PubMed |
| 19 | 30054467 | Predicting treatment benefit in multiple myeloma through simulation of alternative treatment effects. | Nat Commun | 2018 | https://conductscience.org/library/papers/30054467 | PubMed |
| 20 | 38194610 | Genomic Classification and Individualized Prognosis in Multiple Myeloma. | J Clin Oncol | 2024 | https://conductscience.org/library/papers/38194610 | PubMed |
Genes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD1C | 911 | PubTator's text mining | https://conductscience.org/library/genes/911 | NCBI Gene |
| MAF | 4094 | PubTator's text mining | https://conductscience.org/library/genes/4094 | NCBI Gene |
| MAFB | 9935 | PubTator's text mining | https://conductscience.org/library/genes/9935 | NCBI Gene |
| MKI67 | 4288 | PubTator's text mining | https://conductscience.org/library/genes/4288 | NCBI Gene |
| SDC1 | 6382 | PubTator's text mining | https://conductscience.org/library/genes/6382 | NCBI Gene |
| SLFN11 | 91607 | PubTator's text mining | https://conductscience.org/library/genes/91607 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42424601
GET https://conductscience.org/api/papers/v1/42424601/references?page=2